After the vaccine, here’s the 7 billion pill
The American group Merck Sharp & Dohme is the first to announce an effective oral treatment. Green light hoped for at the end of the month.
—
–
“The treatment of MSD will especially make it possible to supplement the deficiencies in vaccination of the poor countries”, estimates the specialist of the pharma Claudia Collin, of AtonRâ Partners. Here, a patient in intensive care at the hospital in Abaetetuba, Brazil, last April.
AFP
Everything remains in abeyance, as during the vaccine race last fall. In green light case, the first oral treatment efficace cobetween the Covids will take on an air of revenge for the American Merck Sharp & Dohme (MSD), ten months after the dismal failure of its own vaccine.
